Failure to address CNS-predominant early neuroinflammatory mediators such as IL-7 and IFN-g, and perhaps more important, the lack of neuroprotective and pro-angiogenic strategies could account for prior failures to modify the course of AD with anti-inflammatory agents [22,158]. This evidence concerns the gene IFNG and Alzheimer disease.